✦ LIBER ✦

Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival

✍ Scribed by Gautam Borthakur; Hagop Kantarjian; Xuemei Wang; William K. Plunkett Jr; Varsha V. Gandhi; Stefan Faderl; Guillermo Garcia-Manero; Farhad Ravandi; Sherry Pierce; Elihu H. Estey

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 117 KB
Volume: 113
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.23927

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Granulocyte-Macrophage colony stimulatin

Granulocyte-Macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia

✍ Paul S. Frenette; Jane F. Desforges; David P. Schenkein; Arthur Rabson; Christop 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 783 KB

Treatment of de novo acute myelogenous l

Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: Effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts

✍ Valent, Peter ;Sillaber, Christian ;Geissler, Klaus ;Andreeff, Michael ;Tafuri, 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 418 KB

GM-CSF is a major regulator of myelopoiesis. Recombinant human GM-CSF (250 micrograms/m2 per day i.v.) was used prior to chemotherapy ("3 + 7" scheme) to recruit leukemic blasts in vivo (de novo AML patients, n = 20) into the chemotherapy sensitive phases of the cell cycle. The stimulatory effect of